Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,401–1,500 of 4,628
Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation
Suhling, H., Bollmann, B. A., & Gottlieb, J. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1220 · Cited by 34
Oxygen Therapy for Interstitial Lung Disease: Physicians’ Perceptions and Experiences
Khor, Y. H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-372oc · Cited by 31
Piotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Evolution and treatment of idiopathic pulmonary fibrosis
Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 29
Central Role of CT in Management of Pulmonary Fibrosis
Chae, K. J., Hwang, H. J., Achcar, R. D., Cooley, J. C., Humphries, S. M., Kligerman, S. J., & Lynch, D. A. (2024) · Radiographics · doi:10.1148/rg.230165 · Cited by 30
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 29
Self-citationDevelopment of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 29
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis
Lee, J. S., & Collard, H. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_17 · Cited by 27
Self-citationBenvéniste, O., Rider, L. G., Aggarwal, R., Allenbach, Y., Benvéniste, O., Bleecker, J. D., de Groot, I., Devilliers, H., Hilton‐Jones, D., Hogrel, J., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.05.014 · Cited by 28
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 29
A standardized herbal extract PM014 ameliorates pulmonary fibrosis by suppressing the TGF-β1 pathway
Kim, K. H., Lee, S., Lee, H., Shin, D., Min, D., Kim, M., Ryu, B., Kim, H. W., & Bae, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-35320-8 · Cited by 27
Wang, B. S., Huang, X., Chen, L. Z., Liu, M. M., & Shi, J. B. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1618291 · Cited by 25
Sugizaki, T., Tanaka, K., Asano, T., Kobayashi, D., Hino, Y., Takafuji, A., Shimoda, M., Mogushi, K., Kawahara, M., & Mizushima, T. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0226-y · Cited by 28
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
Wongkarnjana, A., Scallan, C. J., & Kolb, M. R. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000712 · Cited by 26
“incidence of gastrointestinal adverse effects in treatment groups compared with placebo [39,43].”
BackgroundResultSelf-citationPeyvand, P., Vaezi, Z., Sedghi, M., Dalir, N., Ma’mani, L., & Naderi‐Manesh, H. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1803909 · Cited by 26
Liu, F., Li, W., Chao, Y., Qin, H., Lu, F., Wang, Y., Wang, J., Binbin, C., Na, L., & Zhuang, S. (2020) · Kidney Diseases · doi:10.1159/000509670 · Cited by 30
Ζαννίκου, Μ., Barbayianni, I., Fanidis, D., Grigorakaki, T., Vlachopoulou, E., Konstantopoulos, D., Fousteri, M. I., Nikitopoulou, I., Kotanidou, Α., Kaffe, E., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000862 · Cited by 24
The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
Ubieta, K., Thomas, M. J., & Wollin, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288369 · Cited by 31
Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis
Neys, S. F. H., Heukels, P., van Hulst, J. A. C., Rip, J., Wijsenbeek, M. S., Hendriks, R. W., & Corneth, O. B. J. (2021) · Cells · doi:10.3390/cells10061321 · Cited by 29
“Nintedanib is a tyrosine kinase inhibitor that inhibits signaling downstream of pro-fibrotic receptors, such as fibroblastic and vascular endothelial growth factor receptors (FGFR and VEGFR) [3].”
BackgroundManagement of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
Copeland, C. R., & LANCASTER, L. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.743977 · Cited by 35
“001) (9), similar to efficacy in IPF (11).”
BackgroundInfluentialFatty acid nitroalkene reversal of established lung fibrosis
Koudelka, A., Cechova, V., Rojas, M. M., Mitash, N., Bondonese, A., Croix, C. M. S., Ross, M. A., & Freeman, B. Α. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102226 · Cited by 28
Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04094-0 · Cited by 31
Swigris, J. J., Bushnell, D. M., Rohr, K., Mueller, H., Baldwin, M., & Inoue, Y. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001167 · Cited by 30
Self-citationTargeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis
Lee, S., Lee, C.-M., Ma, B., Kamle, S., Elias, J. A., Zhou, Y., & Lee, C. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826471 · Cited by 32
“In two replicate phase 3 trials, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression (Richeldi et al., 2014).”
BackgroundCharacterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis
Schimmelpennink, M. C., Meek, D. B., Vorselaars, A. D. M., Langezaal, L. C. M., van Moorsel, C. H. M., van der Vis, J. J., Veltkamp, M., & Grutters, J. C. (2022) · Respiratory Research · doi:10.1186/s12931-022-02094-7 · Cited by 26
Salehi, M., Amiri, S., Ilghari, D., Hasham, L. F. A., & Piri, H. (2022) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-022-01081-5 · Cited by 25
Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
Dixon, G., Hague, S., Mulholland, S., Adamali, H. I., Khin, A. M. N., Thould, H., Connon, R., Minnis, P., Murtagh, E., Khan, F., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00529-2023 · Cited by 30
Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases
Schupp, J. C., Köhler, T. C., & Müller–Quernheim, J. (2016) · Respiration · doi:10.1159/000445031 · Cited by 27
Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
Tomioka, H., & Takada, H. (2017) · Respirology Case Reports · doi:10.1002/rcr2.215 · Cited by 28
Are physicians in primary health care able to recognize pulmonary fibrosis?
Purokivi, M., Hodgson, U., Myllärniemi, M., Salomaa, E.-R. M., & Kaarteenaho, R. L. (2017) · European Clinical Respiratory Journal · doi:10.1080/20018525.2017.1290339 · Cited by 32
Evaluation and management approaches for scleroderma lung disease
Schoenfeld, S. R., & Castelino, F. V. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817713680 · Cited by 28
Lambers, C., Boehm, P. M., Lee, S., Ius, F., Jaksch, P., Klepetko, W., Tudorache, I., Ristl, R., Welte, T., & Gottlieb, J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00503-2018 · Cited by 27
Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J. (2019) · Histopathology · doi:10.1111/his.13745 · Cited by 26
“Nintedanib is a tyrosine kinase inhibitor that targets multiple kinases including (in order of potency) vascular endothelial growth factor receptor (VEGFR), lymphocyte-specific protein tyrosine kinase (LCK), fibroblast growth factor receptor (FGFR) and plateletderived growth factor receptor (PDGFR).(3,23) In-vitro exp…”
BackgroundSheu, C., Chang, W., Tsai, M., Liao, S., Chong, I., & Kuo, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030308 · Cited by 27
“Nintedanib, a multi-target tyrosine kinase inhibitor, has been demonstrated to retardate the disease progression in IPF patients [34].”
BackgroundLi, L., Ma, L.-Y., Wang, D., Jia, H., Yu, M., Gu, Y., Shang, H., & Zou, Z. (2019) · Molecules · doi:10.3390/molecules24061108 · Cited by 28
“Unfortunately, treatments for IPF were quite limited, and to date, only two small molecule drugs (Pirfenidone and Nintedanib) were approved by FDA for IPF treatment; nonetheless their treatment effect was not satisfactory [3,4].”
BackgroundShao, R., Wang, F., Lyu, M., Yang, J., Zhang, P., & Zhu, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00412 · Cited by 29
“, 2014), it was striking that only few molecules were shown to reduce disease progression of IPF except pirfenidone and nintedanib (King et al., 2014; Richeldi et al., 2014).”
BackgroundRicheldi, L., Crestani, B., Azuma, A., Kolb, M. R. J., Selman, M., Stansen, W., Quaresma, M., Stowasser, S., & Cottin, V. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.08.002 · Cited by 32
Self-citationMDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 30
Rinciog, C., Diamantopoulos, A., Gentilini, A., Bondue, B., Dahlqvist, C., Froidure, A., Wuyts, W. A., & Soulard, S. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-019-00191-w · Cited by 27
Liang, J., Cao, H., Ke, Y., Sun, C., Chen, W., & Lin, J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00012 · Cited by 26
Kuwana, M., Ogura, T., Makino, S., Homma, S. A., Kondoh, Y., Saito, A., Ugai, H., Gahlemann, M., Takehara, K., & Azuma, A. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1751402 · Cited by 28
Self-citationPesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0126-7 · Cited by 25
Herink, M. C., Irwin, A. N., & Zumach, G. M. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2167 · Cited by 26
“There are no data suggesting a decreased mortality with nintedanib.(35) Other clinically meaningful endpoints reported include acute exacerbation of IPF usually measured by worsening dyspnea, all-cause hospitalizations, and quality of life.”
BackgroundMethodInfluentialTGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation
Wu, M., Wang, Z., Shi, X., Zan, D., Chen, H., Yang, S., Ding, F., Liu, Y., Tan, P., Ma, R. Z., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02533-z · Cited by 28
Jin, H. K., Park, S., Lee, J., Park, H., Jeong, M., Lee, H., Cho, J., & Lee, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.029 · Cited by 29
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis
Hart, S. P., Trawinska, M., & Rupesinghe, R. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81144 · Cited by 28
Todd, J. L., Neely, M. L., Copeland, C., Frankel, C. W., Reynolds, J. M., & Palmer, S. M. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.10.006 · Cited by 28
“While controversy exists regarding the use of physiological endpoints in pulmonary trials(16, 17), it is notable that a precise understanding of the natural history of FVC in untreated patients with IPF was critical to enabling pivotal clinical trials employing FVC decline as the primary endpoint(18, 19).”
MethodThe Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
Kim, Y.-S., Cha, H., Kim, H.-J., Cho, J.-M., & Kim, H.-R. (2019) · Molecules · doi:10.3390/molecules24152792 · Cited by 30
Balestro, E., Cocconcelli, E., Giraudo, C., Polverosi, R., Biondini, D., Lacedonia, D., Bazzan, E., Mazzai, L., Rizzon, G., Lococo, S., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091469 · Cited by 26
“In our study population, antifibrotic therapy slowed down the rate of FVC decline; indeed, IPF patients under treatment lost, on average, approximately 100 mL/year of FVC, which mirrors what has been observed both in clinical trials [17,18] and in a number of real-world studies [19–21].”
ResultCharacterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data
Mortimer, K. M., Bartels, D. B., Hartmann, N., Capapey, J., Yang, J., Gately, R. V., & Enger, C. L. (2020) · Respiration · doi:10.1159/000504630 · Cited by 28
Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis
Uchida, Y., Ikeda, S., Sekine, A., Katano, T., Tabata, E., Oda, T., Okuda, R., Kitamura, H., Baba, T., Komatsu, S., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.08.003 · Cited by 25
Udwadia, Z. F., Pokhariyal, P. K., Tripathi, A. K. R., & Kohli, A. (2020) · Lung India · doi:10.4103/lungindia.lungindia_533_20 · Cited by 26
Antifibrotic Role of Nintedanib in Tracheal Stenosis After a Tracheal Wound
Fan, Y., Li, X., Fang, X., Liu, Y., Zhao, S., Yu, Z., Tang, Y., & Wu, P. (2021) · The Laryngoscope · doi:10.1002/lary.29618 · Cited by 28
Chen, C., Lin, H.-C., Wang, Y., Wang, C., Lin, Y. S., & Lai, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251636 · Cited by 31
“Adverse events were defined according to the FDA and previous studies, including TOMORROW [6], INPULSIS [7], NCT01979952 [25], INBUILD [15] and SENSCIS [14].”
BackgroundMethodInfluentialAwake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study
Guerrera, F., Costardi, L., Rosboch, G. L., Lybéris, P., Ceraolo, E., Solidoro, P., Filippini, C., Verri, G., Brazzi, L., Albera, C., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00630-2020 · Cited by 26
Takahashi, T., Terada, Y., Pasque, M. K., Liu, J., Byers, D. E., Witt, C. A., Nava, R. G., Puri, V., Kozower, B. D., Meyers, B. F., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.036 · Cited by 29
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01587-3 · Cited by 27
Li, X., Yu, R., Wang, P., Wang, A., & Huang, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147643 · Cited by 29
Inspiratory muscle training in interstitial lung disease: a systematic scoping review
Hoffman, M. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210089 · Cited by 35
Nambiar, A. M., Walker, C. M., & Sparks, J. A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211039771 · Cited by 28
Mackintosh, J. A., Pietsch, M., Lutzky, V. P., Enever, D., Bancroft, S., Apte, S. H., Tan, M. E., Yerkovich, S. T., Dickinson, J. L., Pickett, H. A., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001127 · Cited by 32
The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study
Plantier, L., Smolinska, A., Fijten, R., Flamant, M., Dallinga, J. W., Mercadier, J.-J., Pachen, D. M. F. A., d’Ortho, M., van Schooten, F., Crestani, B., et al. (2022) · Respiratory Research · doi:10.1186/s12931-021-01923-5 · Cited by 29
Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis
DeDent, A. M., Collard, H. R., & Thakur, N. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.042 · Cited by 26
Self-citationSanders, J. L., Axelsson, G. T., Putman, R. K., Menon, A. A., Dupuis, J., Xu, H., Wang, S., Murabito, J. M., Vasan, R. S., Araki, T., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218315 · Cited by 25
Choi, B., Adan, N. M., Doyle, T. J., Estépar, R. S. J., Harmouche, R., Humphries, S. M., Moll, M. R., Cho, M. H., Putman, R. K., Hunninghake, G. M., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.030 · Cited by 27
Achkar, M. A., Jamal, O., & Chaaban, T. A. (2022) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_103_22 · Cited by 26
“142 Annals of Thoracic Medicine - Volume 17, Issue 3, July-September 2022 disease progression.[50,51] Nintedanib was also shown to be beneficial in progressive fibrosing ILDs including scleroderma, connective tissue disease‐ILD, and sarcoidosis.”
BackgroundWang, L., Shao, M., Jiang, W., & Huang, Y. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.101953 · Cited by 35
Knipe, R. S., Nurunnabi, M., Probst, C. K., Spinney, J. J., Abe, E. A., Bose, R. J., Ha, K., Logue, A., Nguyen, T. H., Servis, R. L., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00086.2022 · Cited by 29
Boutel, M., Boutou, A., Pitsiou, G., Garyfallos, A., & Dimitroulas, T. (2023) · Diagnostics · doi:10.3390/diagnostics13071221 · Cited by 29
“controlled trial—and the INPULSIS trials—two duplicate, phase III trials—established nintedanib as an antifibrotic treatment for idiopathic pulmonary fibrosis, as patients who received nintedanib had a significant improvement in FVC decline compared to the placebo group [28,29].”
BackgroundEffect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
de Andrade, J. A., Neely, M. L., Hellkamp, A. S., Culver, D. A., Kim, H. J., Liesching, T. N., Lobo, L. J., Ramaswamy, M., Safdar, Z., Bender, S. D., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.03.003 · Cited by 29
Lung function trajectories in patients with idiopathic pulmonary fibrosis
Neely, M. L., Hellkamp, A. S., Bender, S. D., Todd, J. L., Liesching, T. N., Luckhardt, T., Oldham, J. M., Raj, R., White, E. S., & Palmer, S. M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02503-5 · Cited by 31
Ruaro, B., Salotti, A., Reccardini, N., Kette, S., Re, B. D., Nicolosi, S., Zuccon, U., Confalonieri, M., Mondini, L., Pozzan, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17010119 · Cited by 30
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Pugashetti, J. V., & Lee, J. S. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1782218 · Cited by 32
Nishimoto, T., Mlakar, L., Takihara, T., & Feghali‐Bostwick, C. A. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.039 · Cited by 25
Morell, F., Esser, D., Lim, J. T., Stowasser, S., Villacampa, A., Nieves, D., & Brosa, M. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0168-6 · Cited by 25
Self-citationTherapeutic advances in idiopathic pulmonary fibrosis
Fraser, E., & Hoyles, R. K. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-1-42 · Cited by 28
White, E. S., Borok, Z., Brown, K. M., Eickelberg, O., Günther, A., Jenkins, G. R., Kolb, M. R. J., Martínez, F. J., Roman, J., & Sime, P. J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0254st · Cited by 32
Self-citationAdvances in understanding the immunopathology of sarcoidosis and implications on therapy
Cinetto, F., & Agostini, C. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1181541 · Cited by 26
Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 26
Self-citationProtective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice
Tanaka, K., Niino, T., Ishihara, T., Takafuji, A., Takayama, T., Kanda, Y., Sugizaki, T., Tamura, F., Kurotsu, S., Kawahara, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03676-y · Cited by 30
Is It Idiopathic Pulmonary Fibrosis or Not?
Salvatore, M. M., Ishikawa, G., & Padilla, M. L. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.01.170288 · Cited by 24
Clinical Genetics in Interstitial Lung Disease
Newton, C. A., Molyneaux, P. L., & Oldham, J. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00116 · Cited by 29
Sadeleer, L. D., Verleden, S. E., Dycker, E. D., Yserbyt, J., Verschakelen, J., Verbeken, E. K., Nemery, B., Verleden, G. M., Hermans, F., Vanaudenaerde, B. M., et al. (2018) · Respirology · doi:10.1111/resp.13342 · Cited by 27
Kashiwada, T., Saito, Y., Terasaki, Y., Hisakane, K., Takeuchi, S., Sugano, T., Miyanaga, A., Noro, R., Minegishi, Y., Seike, M., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy180 · Cited by 24
“Nintedanib, a tyrosine kinase inhibitor (TKI) that targets VEGF receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor is used to treat idiopathic pulmonary fibrosis, and it has been suggested that nintedanib reduces the risk of AE (24).”
BackgroundKawamura, K., Ichikado, K., Ichiyasu, H., Anan, K., Yasuda, Y. U., Suga, M., & Sakagami, T. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0880-0 · Cited by 26
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 28
A novel mechanoeffector role of fibroblast S100A4 in myofibroblast transdifferentiation and fibrosis
Southern, B. D., Li, H., Mao, H., Crish, J. F., Grove, L. M., Scheraga, R. G., Mansoor, S., Reinhardt, A., Abraham, S., Deshpande, G. M., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105530 · Cited by 27
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 26
Wu, Z., Shi, R., Yan, S., Zhang, S., Lü, B., Huang, Z., & Ji, L. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155368 · Cited by 27
Arslan, A., Smith, J., Qureshi, M. R., Uysal, A., Patel, K., Herazo‐Maya, J. D., & Bandyopadhyay, D. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1306032 · Cited by 33
de Mattos, W. L. L. D., Khalil, N., Spencer, L. G., Bonella, F., Folz, R. J., Rolf, J. D., Moğulkoç, N., LANCASTER, L. H., Jenkins, G. R., Lynch, D. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1907oc · Cited by 27
Self-citationHoffman, E. T., Shah, A., Barboza, W. R., Rodríguez, L. R., Dherwani, R., Dooley, P. E., Minakin, K., Tomer, Y., Ayers, L. J., Jones, D. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63735-1 · Cited by 48
Lotz-Jenne, C., Lüthi, U., Ackerknecht, S., Lehembre, F., Fink, T., Stritt, M., Wirth, M., Pavan, S., Bill, R., Regenass, U., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8418 · Cited by 27
Park, J., Lee, Y. J., Lee, J., Park, S. S., Cho, Y., Lee, S., Kim, Y. W., Han, S. K., & Yoo, C. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.346 · Cited by 24
McCarthy, C., Gallego, B. L., Trapnell, B. C., & McCormack, F. X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67144-4_24 · Cited by 27
Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire
PESaM Collaborating Group, Kimman, M., Wijsenbeek, M. S., van Kuijk, S. M. J., Wijnsma, K. L., van de Kar, N. C. A. J., Storm, M., van Jaarsveld, X., & Dirksen, C. D. (2018) · Patient · doi:10.1007/s40271-018-0340-6 · Cited by 26
Role of bone marrow mesenchymal stem cells in the development of PQ‑induced pulmonary fibrosis
Chen, J., Si, L., Zhou, L., & Deng, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9976 · Cited by 25
Bárczi, E., Starobinski, L., Kolonics-Farkas, A. M., Eszes, N., Bohács, A., Vašáková, M., Hejduk, K., & Müller, V. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00906-9 · Cited by 27
Chen, L., & Zhao, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214441 · Cited by 24
Yu, X., Yang, S.-G., Xie, Y., & Li, J. (2019) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2019.12.005 · Cited by 25
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.